Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Impact BioMedical (IBO): A Technical Path Back to $10.50 and +104% Upside?

Impact BioMedical (IBO): A Technical Path Back to $10.50 and +104% Upside?

Key Takeaways

  • The $10.50 level is not an analyst consensus target; Impact BioMedical Inc. (IBO) lacks meaningful sell-side coverage, so it reflects the stock's 52-week high as a technical reference point.
  • At the latest verified price near $5.14, reaching $10.50 would imply upside of roughly 104%, a substantial move even for this micro-cap name.
  • No formal analyst price target range exists; any such figure should be viewed as a speculative or technical marker rather than a reliable forecast.
  • Potential supports include a pending merger with Zoar Ltd., a recent reverse stock split to maintain the NYSE American listing, and an IP portfolio centered on the Linebacker platform.
  • Key risks involve minimal revenue, ongoing losses, limited cash reserves, dilution potential, and the high volatility common to early-stage biotechs.
  • Additional details are available on the company's Major News, Today's Price Move, Forecast, and Earnings pages.

How the $10.50 Level Emerged

Impact BioMedical Inc. (IBO) operates as a Houston-based biotech holding company with roughly two full-time employees and trailing-twelve-month revenue around $38,000. Its early-stage profile means mainstream analysts do not issue price targets, and standard data sources show no coverage or consensus. The $10.50 figure therefore stems from public references to the stock's 52-week high, which ranged between about $10.47 and $10.51 and rounds to $10.50. This marks a prior peak and technical resistance area, not a valuation-driven projection. It poses the question of whether the shares could revisit that recent high rather than predicting an outcome.

Current Position and Route to the Target

The stock closed near $5.14 in mid-November 2026, well below its 52-week high of roughly $10.51 yet above the low of about $2.43. Closing the gap to $10.50 would require a gain of approximately 104%, a sizable advance for any equity and particularly one with a beta near 2.9 that trades on limited volume. Progress would likely hinge more on event catalysts than near-term fundamentals, given negligible revenue and continued losses. A completed merger with Zoar Ltd. might reshape the capital structure, while licensing advances on the Linebacker platform, already licensed to ProPhase Laboratories for oncology uses, could influence sentiment. Without those drivers, any move would depend mainly on technical momentum.

Factors That Could Aid a Move Higher

The pending combination with Zoar Ltd. stands out as the primary potential catalyst, especially following the 1-for-12.62 reverse split executed to support exchange compliance. Successful completion could change share count, liquidity, and strategic focus. The company's patent holdings cover oncology, anti-inflammatory, antiviral, and wellness applications, including Linebacker, Laetose, Equivir, and 3F platforms, any of which might lead to licensing or royalty deals. The reverse split helps preserve listing status, and trading above the 50-day moving average recently indicates short-term technical support.

Obstacles That Could Limit Upside

Challenges remain significant. Revenue of around $38,000 is negligible, and the company posted a net loss of approximately $11.87 million for fiscal 2025, with cash at about $21,000 and negative operating cash flow. Operations rely on financing, licensing revenue, or the merger outcome, and additional share issuance would dilute holders. Governance risks include multiple prior reverse splits, such as the 1-for-55 action in 2023, plus majority ownership by DSS BioHealth Security. Institutional ownership stays low, the float is limited, and volatility is extreme, so sustained interest needed for a retest of $10.50 is not assured.

Key Technical Levels

The $10.50 zone represents the main resistance at the 52-week high. Intermediate markers include the 200-day moving average near $6.18 and the 50-day moving average around $4.88. Support levels feature the October 2026 swing low near $2.68 and the 52-week low of about $2.43. To make $10.50 attainable, the stock would likely need to reclaim and hold the 200-day average first.

Monitoring Points for Investors

With no formal 12-month analyst target, the $10.50 level lacks a defined research horizon. Focus should remain on the Zoar Ltd. merger status and terms, any resulting share-count adjustments, licensing or royalty updates, quarterly cash positions and losses, and exchange compliance notices. Regulatory developments around the therapeutic platforms and overall market appetite for speculative biotech names also matter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Final Assessment

The $10.50 reference is a technical milestone tied to the 52-week high rather than an analyst-derived valuation. From the recent price near $5.14, it would demand a move of roughly 104%. Support rests primarily on catalysts such as the Zoar Ltd. merger and IP progress, against a backdrop of minimal revenue, recurring losses, thin cash, and repeated reverse splits. No credible consensus exists, and the outcome remains highly uncertain. Investors should treat the level as a reference to watch against news flow rather than a guaranteed destination.

Using AI Daily Buy/Sell Signals in Practice

In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track momentum shifts across volatile names like this one. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical patterns. For a development-stage biotech with thin trading, these signals help surface potential changes in trend or momentum without replacing broader due diligence. I find them useful for refining entry and exit ideas alongside other analysis, though they serve best as one input among several.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBO

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


IBO's RSI Indicator climbs out of oversold territory

The RSI Indicator for IBO moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 9 similar instances when the indicator left oversold territory. In 8 of the 9 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on IBO as a result. In 32 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for IBO just turned positive on October 23, 2026. Looking at past instances where IBO's MACD turned positive, the stock continued to rise in 13 of 15 cases over the following month. The odds of a continued upward trend are 87%.

IBO moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +19.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 28 of 32 cases where IBO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IBO broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. IBO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (3.586). P/E Ratio (0.369) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
1400 Broadfield Boulevard
Phone
+1 281 415-6576
Employees
2
Web
https://www.impactbiomedinc.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.